SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1 - Wang, Qian; Guo, Yicheng; Schwanz, Logan T.; Mellis, Ian A.; Sun, Yiwei; Qu, Yiming; Urtecho, Guillaume; Valdez, Riccardo; Stoneman, Emily; Gordon, Aubree; Wang, Harris H.; Ho, David D.; et al. (Emerging microbes & infections, 2024)
Keywords: Angiotensin-Converting Enzyme 2 - genetics; Angiotensin-Converting Enzyme 2 - metabolism; Antibodies; Antibodies, Neutralizing - immunology; Antibodies, Viral - blood; Antibodies, Viral - immunology; BA.2.87.1; Cell Line; Chemical bonds; COVID-19; COVID-19 - immunology; COVID-19 - virology; Drug dosages; EG.5.1; Emerging and Re-Emerging Coronaviruses; Humans; Immune Evasion; Infections; Infectious diseases; JN.1; mRNA vaccines; Mutation; Neutralization Tests; polyclonal sera; mRNA vaccines; Proteins; Research Letter; SARS-CoV-2; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; Surgeons; Viruses; COVID-19; EG.5.1; SARS-CoV-2; receptor engagement; JN.1; BA.2.87.1; antibody evasion; viral infectivity; polyclonal sera; mRNA vaccines